Journal
CURRENT MEDICINAL CHEMISTRY
Volume 11, Issue 7, Pages 887-900Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/0929867043455648
Keywords
-
Funding
- NCI NIH HHS [1 R43 CA84828, 1 R43 CA88578] Funding Source: Medline
- NIAID NIH HHS [1 R43 AI 056859] Funding Source: Medline
Ask authors/readers for more resources
IMP dehydrogenase, the key enzyme in de novo synthesis of purine nucleotides, is an important therapeutic target. Three inhibitors of IMP dehydrogenase reached the market; ribavirin (Rebetol) a broad-spectrum antiviral agent, which in combination with interferon-a is now used for treatment of hepatitis C virus infections, mizoribine (Bredinin) and mycophenolic mofetil (CellCept) have been introduced as immunosuppressants. Numerous novel inhibitors are under development. This review describes recent progress in the development of new drugs based on inhibition of IMP dehydrogenase.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available